All News

2018

March

Media Release / Mar 20, 2018

Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies

Read More
Media Release / Mar 01, 2018

Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis

Read More

January

Media Release / Jan 03, 2018

Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer

Read More
2017

December

Media Release / Dec 06, 2017

Kisqali® first and only CDK4/6 inhibitor to show superior efficacy vs. oral endocrine therapy as 1L treatment in randomized Phase III trial in premenopausal women with HR+/HER2- advanced breast cancer

Read More

November

Media Release / Nov 14, 2017

Novartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy

Read More
Media Release / Nov 08, 2017

Novartis reports positive results from Phase III trial of Kisqali® (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer

Read More

September

Media Release / Sep 28, 2017

Novartis and UC Berkeley collaborate to tackle 'undruggable' disease targets

Read More

August

Media Release / Aug 24, 2017

Novartis Kisqali® (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor

Read More

June

Media Release / Jun 23, 2017

Novartis Kisqali® (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor

Read More
Media Release / Jun 02, 2017

Novartis presents updated data that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer

Read More

Pages

Related Links

Annual Report 2017

Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.

Learn More